Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) – Research analysts at Chardan Capital boosted their FY2023 earnings per share estimates for shares of Pear Therapeutics in a report issued on Monday, April 3rd. Chardan Capital analyst K. Nakae now forecasts that the company will post earnings per share of ($0.56) for the year, up from […]
Pear Therapeutics (NASDAQ:PEAR – Get Rating) and GeneDx (NASDAQ:WGS – Get Rating) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their risk, earnings, profitability, institutional ownership, dividends, analyst recommendations and valuation. Analyst Recommendations This is a summary of recent recommendations for […]
Credit Suisse Group cut shares of Pear Therapeutics (NASDAQ:PEAR – Get Rating) from an outperform rating to a neutral rating in a research note issued to investors on Monday, The Fly reports. Separately, BTIG Research cut shares of Pear Therapeutics from a buy rating to a neutral rating in a research report on Friday, March […]
Let’s start up with the current stock price of Pear Therapeutics Inc. (PEAR), which is $2.13 to be very precise. The Stock rose vividly during the last session to $2.13 after opening rate of $1.69 while the lowest price it went was recorded $1.6119 before closing at $1.75.Recently in News on Septe
Pear Therapeutics, Inc. (NASDAQ:PEAR – Get Rating) saw a significant decrease in short interest during the month of May. As of May 31st, there was short interest totalling 1,150,000 shares, a decrease of 19.6% from the May 15th total of 1,430,000 shares. Based on an average daily volume of 319,800 shares, the days-to-cover ratio is […]